Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$42.93 USD

42.93
1,631,798

-1.74 (-3.90%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $42.92 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EXAS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Exact Sciences Corporation [EXAS]

Reports for Purchase

Showing records 221 - 240 ( 366 total )

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 221

03/20/2014

Company Report

Pages: 8

NEJM Publication Confirms Clinical Value

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 222

03/20/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 223

03/19/2014

Company Report

Pages: 10

Publication of Full DEEP-C Data Supportive of Positive FDA Review Next Week, Market Uptake

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 224

03/18/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 225

03/16/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 226

03/10/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 10

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 227

02/28/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 228

02/21/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 229

02/21/2014

Daily Note

Pages: 19

Morning Call

Provider: The Benchmark Company

Price: 50.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 230

02/21/2014

Company Report

Pages: 6

4Q As Expected Publication, Panel, and Commercial Prep in Focus

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 231

02/20/2014

Company Report

Pages: 13

Ready for Launch, Price Target Increase As Model Reflects Another Year of Sales

Provider: The Benchmark Company

Analyst: WALD J

Price: 50.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 232

02/20/2014

Company Report

Pages: 10

4Q13 Recap - Good Tone on Imminent Publication & Reimbursement - Contract Sales Partner Announced & Economics Seem Better - Maintain OP - PT to $15

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 233

02/14/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 234

02/13/2014

Company Report

Pages: 9

Expecting Uneventful 4Q13 Earnings - Pivotal Publication Any Day & FDA March Panel Meeting Key - Raising PT to $14 - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 235

01/08/2014

Industry Report

Pages: 4

Preannouncement Watch - Look for Med Tech News into Next Week?s HC Conference

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 236

12/05/2013

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 237

12/04/2013

Daily Note

Pages: 6

Morning Call

Provider: The Benchmark Company

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 238

12/04/2013

Company Report

Pages: 10

FDA Advisory Panel Set for March 26

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 239

12/04/2013

Daily Note

Pages: 2

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 240

12/04/2013

Daily Note

Pages: 5

PMA Progress Continues - Panel Date Announced

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 10.00

Research Provided by a Third Party